Beauty Health (SKIN) Q2 2025: Consumables Top 70% of Revenue as Device Sales Lag
Beauty Health’s recurring consumables revenue surpassed 70% of total sales, underscoring a durable shift to a Razor-Razor Blade model even as device sales remain pressured by macro headwinds. Margin expansion, cost discipline, and a growing installed base signal progress on transformation, but persistent device churn and China transition drag on near-term growth. Investors should watch for the impact of new product launches and the evolving provider loyalty program as key levers for future upside.
Summary
- Consumables Dominate Revenue Mix: Recurring consumables now exceed 70% of total sales, reinforcing business model durability.
- Device Sales Remain Under Pressure: Macro challenges and higher churn limit installed base growth despite cost and margin gains.
- Innovation Pipeline and Loyalty Relaunch: New boosters, backbar, and a 2026 loyalty program aim to deepen provider engagement and drive future growth.
Performance Analysis
Beauty Health delivered another quarter of outperformance versus guidance, with both revenue and adjusted EBITDA exceeding expectations for the third consecutive period. The company’s Razor-Razor Blade model—where device sales drive recurring consumables purchases—has become more pronounced, as consumables comprised over 70% of revenue. This shift is pivotal: consumables, which are used in each facial treatment, provide higher margin, recurring revenue and greater predictability compared to lumpy device sales.
Gross margin improvement was notable, driven by a favorable sales mix, inventory optimization, and disciplined cost control. Operating expenses fell nearly 18%, led by lower sales and marketing outlays and G&A reductions, including bad debt recoveries. The installed base of active devices grew to over 35,000 units, but net additions slowed due to elevated churn and ongoing capital equipment headwinds. Device sales declined year over year, reflecting macroeconomic pressures, particularly in the Americas and APAC regions. The company’s transition to a distributor model in China also weighed on both revenue and average selling prices (ASPs).
- Consumables Resilience: Excluding China, consumables revenue rose 6.3% in the U.S. national accounts, and global booster sales increased double digits, highlighting robust end-consumer demand.
- Device Churn and ASP Compression: Higher churn and greater sales of lower-priced or refurbished devices diluted installed base growth and pressured margins.
- Cost and Margin Gains: Operating loss narrowed sharply, and adjusted EBITDA outpaced expectations due to cost discipline and improved gross profit mix.
Despite these positives, the business remains exposed to macro and channel headwinds, with the China transition, tariff impacts, and device churn tempering the pace of recovery.
Executive Commentary
"Q2 marked another strong quarter, demonstrating the momentum of our transformation strategy and disciplined execution. We exceeded both revenue and adjusted EBITDA guidance for the third consecutive quarter, driven by our consumables revenue, margin expansion, and operational improvements."
Marla Beck, Chief Executive Officer
"While there's still work to be done to grow equipment device sales, we are successfully controlling our costs to drive increased adjusted EBITDA and cash flow. As a result of our favorable performance in the first half of 2025, we are increasing the low end of our net sales full year guidance range."
Michael Monahan, Chief Financial Officer
Strategic Positioning
1. Razor-Razor Blade Model Deepens Moat
With consumables now over 70% of revenue, Beauty Health’s recurring revenue engine is firmly established. Each device placement creates an annuity-like stream from consumable sales, making the business less dependent on volatile capital equipment cycles. Booster launches and clinical validation have further strengthened this model, as providers see tangible ROI and remain loyal.
2. Innovation Pipeline Targets Provider Stickiness
New product launches—including the Hydrophilic with Pep9 booster and upcoming backbar and skincare lines—are designed to expand share of wallet with providers. The “beyond the treatment room” strategy aims to embed Beauty Health deeper into provider workflows, increasing utilization and lifetime value. The company plans to maintain a steady cadence of one to two booster launches per year to maximize adoption and revenue per provider.
3. China Distributor Transition and Tariff Navigation
The shift from direct sales to a distributor model in China is a double-edged sword: it reduces opex and tariff exposure but results in lower ASPs and gross margin. The company has warehoused enough equipment to avoid most device tariffs through year-end, but consumables will still face about $4 million in tariff costs in the back half. This transition year will likely weigh on overall growth but sets up a leaner, more flexible China business for 2026.
4. Sales Organization Overhaul and CRM Investments
Leadership has rebuilt the sales organization, hiring a new chief revenue officer and deploying a data-driven CRM system to improve pipeline management and lead conversion. These efforts, coupled with a new global engagement program, are intended to reverse recent device churn and accelerate installed base growth as macro conditions improve.
5. Loyalty Program Relaunch for 2026
A redesigned provider loyalty program will launch in early 2026, adding new tiers and perks to reward long-term engagement and incentivize adoption of new products like backbar and skincare. With 93% of providers already enrolled, this program could become a powerful lever for incremental sales and retention.
Key Considerations
Beauty Health’s transformation is yielding tangible results, but the company must carefully balance innovation, cost control, and channel management to sustain momentum in a volatile environment.
Key Considerations:
- Recurring Revenue Stability: Consumables growth and high provider retention provide a buffer against device sales volatility.
- Device Churn Mitigation: Elevated churn and sluggish net adds highlight the need for effective reactivation and new customer acquisition strategies.
- China Transition Drag: Distributor model lowers costs but compresses ASPs and margins; full benefits likely delayed until 2026.
- Tariff and FX Exposure: Tariff headwinds in APAC and currency volatility could pressure gross margin and earnings in the back half.
- Execution on Innovation: Timely and successful launches of boosters, backbar, and skincare lines are critical to offsetting device headwinds and driving incremental growth.
Risks
Persistent macroeconomic uncertainty, especially in capital equipment spending, continues to pressure device sales and installed base growth. The China distributor transition introduces ASP and margin risk, while tariff exposure remains a material cost headwind. Elevated device churn, if not reversed, could erode future consumables growth and undermine the recurring revenue thesis. Any delays or missteps in the innovation pipeline or loyalty program relaunch could limit upside and weaken provider engagement.
Forward Outlook
For Q3 2025, Beauty Health guided to:
- Net sales between $65 million and $70 million
- Adjusted EBITDA between $2 million and $4 million
For full-year 2025, management raised the low end of guidance:
- Net sales of $285 million to $300 million
- Adjusted EBITDA of $27 million to $35 million
Management highlighted:
- Seasonal Q3 softness and continued macro headwinds, especially in device sales
- Tariff costs and increased R&D investment will weigh on second-half margins
Takeaways
Beauty Health’s pivot to a consumables-driven model is showing resilience, but device sales and churn remain the critical swing factors for growth and margin trajectory.
- Recurring Revenue Engine: Consumables now anchor the business, providing margin stability and predictable cash flow, but future growth depends on expanding the installed base.
- Transformation Progress: Cost discipline, margin expansion, and innovation investment are delivering results, but China and device sales are near-term drags.
- Watch for Execution: Provider reactivation, innovation launches, and loyalty program rollout are the key levers to monitor for inflection in growth and profitability.
Conclusion
Beauty Health’s Q2 results validate its transformation strategy, with recurring revenue and margin gains offsetting device market weakness. Sustained execution on innovation and channel management will be essential to unlock the next phase of growth and restore investor confidence in the installed base expansion narrative.
Industry Read-Through
The shift toward recurring consumables revenue and provider-centric innovation is becoming table stakes in the medical aesthetics and device sector. Beauty Health’s experience highlights the vulnerability of capital equipment sales to macro shocks, and the importance of building annuity-like revenue streams through consumables and services. Competitors and adjacent players should note the operational and strategic value of loyalty programs, CRM-driven sales execution, and a disciplined approach to product cadence. The China distributor transition also offers a cautionary tale on balancing growth with profitability and risk mitigation in international markets.